Merck stock holds steady near 52 week high as FY 2026 guidance frames Keytruda momentum

Published on 08/28/2026 at 07:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Merck stock is trading close to its 52 week high as investors weigh a strong second quarter revenue print and FY 2026 EPS guidance against a cautious analyst rating backdrop.

Geometrisches Bauhaus-Poster mit dem Wort PHARMA in kräftigen Farben — Bauhaus-Poster mit Schriftzug PHARMA visualisiert Branche von Merck & Co. Inc., ISIN US58933Y1055, geometrisch abstrakt, Illustration mit AI erstellt.

Merck & Co., Inc. (US58933Y1055) stock is trading close to its recent 52 week high in late August 2026 as investors digest a solid second quarter revenue print and full year EPS guidance that frame the outlook for its oncology portfolio, led by Keytruda, as of August 27, 2026.

Per a recent market snapshot, Merck stock traded at $153.21 on August 27, 2026, with a reported market capitalization of $378.00 billion and year to date performance of 0.58 percent, underlining how far the shares have come since the past year low of $77.58 highlighted in a separate performance overview.

The latest figures sit against fresh FY 2026 guidance for earnings per share of $2.66 to $2.76, providing a numerical frame for how management sees the current year playing out following the second quarter release of August 4, 2026.

Second quarter 2026 results set the tone

Merck & Co., Inc. reported revenue of $16.61 billion for the second quarter of 2026, with the reporting period ending in the first half of 2026 and disclosed in early August 2026, making this the most recent quarterly snapshot available as of August 28, 2026.

Compared with the same period a year earlier, when second quarter revenue stood at $15.10 billion according to a historical comparison in the same overview, this represents an increase of $1.51 billion, or 10.0 percent year over year, underscoring that Merck is still in a growth phase despite a more mature product portfolio.

The company’s oncology franchise, centered on the PD 1 inhibitor Keytruda, continues to be a major driver of that top line, with oncology segment revenue cited as $8.40 billion in the second quarter of 2026 versus $7.40 billion in the second quarter of 2025, a gain of $1.00 billion that translates into segment growth of 13.5 percent year over year.

On the bottom line, Merck reported second quarter 2026 EPS of $0.72, compared with $0.64 in the second quarter of 2025, an increase of $0.08 per share or 12.5 percent, which ties directly into the full year 2026 guidance band of $2.66 to $2.76 set out in recent commentary on the company’s outlook.

That guidance range implies that the $0.72 posted in the second quarter represents between 26.1 percent and 27.1 percent of the low and high ends of the full year target, suggesting that Merck needs to deliver at least similar or slightly stronger performance in the second half of 2026 to meet its stated objectives.

Guidance and analyst expectations

Fresh coverage notes that Merck has set FY 2026 guidance at EPS of $2.66 to $2.76, and that analyst consensus currently sits at 2.76 EPS for the full year, aligning the upper edge of management’s band with the Street’s central expectation.

This alignment means that Merck is not promising a stretch target beyond what analysts expect, but it does commit the company to maintaining the second quarter 2026 pace or modestly improving margins or revenue in subsequent quarters to avoid falling short of the 2.76 EPS consensus.

In valuation terms, taking the $153.21 share price from August 27, 2026 and the consensus EPS of 2.76 yields a forward price earnings multiple of 55.5, a level that reflects investors’ willingness to pay a premium for Merck’s pipeline and cash flows, but which also raises the bar for future execution.

Recent rating commentary describes Merck as a moderate buy on average, but one detailed note explains that some analysts have kept a hold stance with a price target of $150.00 even as the shares traded at $156.45 the previous session, effectively putting the stock above that particular target and implying limited upside in that view.

The fact that Merck shares traded above the cited $150.00 price target in that rating example illustrates the tension between a strong operational story and more cautious valuation arguments, and highlights why any slippage against the EPS guidance or unexpected pipeline setbacks could weigh on sentiment.

Keytruda and cancer vaccine momentum

Operationally, Merck’s Keytruda remains central to the investment case, not only as a standalone immunotherapy but also as part of combination approaches with personalized cancer vaccines.

A recent briefing on developments in oncology notes that a personalized mRNA cancer vaccine developed together with Moderna, described under the name intismeran autogene, is being used alongside Keytruda after surgical tumor removal in high risk melanoma patients, which underscores Merck’s role in advancing cutting edge immuno oncology regimens.

This combination strategy is important for investors because it indicates that Keytruda can extend its clinical and commercial reach beyond monotherapy indications, potentially supporting longer revenue tails as new tumor types and stages are addressed in partnership settings.

At the same time, such complex regimens come with regulatory and reimbursement challenges, and the investment thesis therefore hinges not only on clinical success but also on the ability to secure favorable coverage and pricing conditions in key markets over the coming years.

Merck’s collaboration work in personalized vaccines also has strategic implications beyond melanoma, as the underlying algorithm and manufacturing processes could be adapted for other solid tumors, expanding the addressable market and deepening the company’s oncology moat if outcomes remain favorable.

Share price context and technical picture

From a market perspective, the $153.21 price level as of August 27, 2026 sits just below the $154.49 52 week high referenced in a broader stock performance analysis, meaning Merck stock is trading within 0.8 percent of its peak over the past year.

The same overview points out that Merck shares once traded at a low of $77.58 over the past year, so the move to the current band represents a gain of $75.63 or 97.4 percent from that trough, a dramatic recovery for a large cap pharmaceutical name and a signal of how much expectations have rebounded.

Daily trading data from August 26, 2026 show Merck opening at $156.54 and closing at $153.21 with an intraday high and low contained within that range and volume of 8.63 million shares, highlighting that liquidity remains strong but that the stock has seen some recent pullback from the mid $150s.

In this context, the $150.00 price target cited in the hold rating example sits below the recent close and suggests that at least some valuation models assume a consolidation or mild correction rather than continued breakouts to new highs.

For investors, the technical story therefore centers on whether the $154.49 52 week high can be sustainably exceeded on the back of operational news, or whether the stock will oscillate between the $150.00 target area and the low $150s as the market waits for the next major data release or guidance update.

Product spotlight Keytruda in melanoma

A representative product that captures Merck’s current growth profile is the immunotherapy Keytruda, which has become a standard of care in several cancers and is central to the company’s melanoma strategy.

In high risk melanoma patients who have undergone surgical tumor removal, Keytruda is being used in combination with the personalized mRNA cancer vaccine intismeran autogene, a regimen designed to train the immune system to recognize residual cancer cells while Keytruda lifts the immune brakes.

This approach aims to reduce recurrence rates compared with either surgery alone or non personalized therapies, and if ongoing and future trials confirm that benefit with acceptable safety, it would underpin Merck’s ability to sustain and grow oncology revenues beyond current indications.

Keytruda’s success has already transformed Merck’s revenue mix, with oncology contributing a growing share of the $16.61 billion second quarter 2026 revenue figure, and the melanoma vaccine partnership marks a new chapter where customized therapies and immunotherapies are tightly integrated.

For retail investors, the takeaway is that Merck’s product story is increasingly tied to sophisticated immuno oncology combinations rather than traditional small molecule drugs, which could offer durable growth but also raises the scientific and regulatory complexity of its pipeline.

Merck stock and current market view

Merck & Co., Inc. is listed on the NYSE under the ticker MRK, and its latest market data snapshot shows the shares at $153.21 as of August 27, 2026, with a market cap of $378.00 billion, placing it firmly in the large cap bracket of US equities.

The proximity of the share price to the 52 week high at $154.49 and its significant climb from the $77.58 low illustrate that Merck stock has delivered substantial gains over the past year, but the modest 0.58 percent year to date performance as cited in one snapshot indicates that much of that rally occurred earlier and that the current year has been flatter.

With FY 2026 EPS guidance of $2.66 to $2.76 and consensus at 2.76, the stock’s current valuation leaves limited room for disappointment, making the next set of quarterly numbers and any updates on Keytruda and its cancer vaccine collaborations critical catalysts for whether Merck shares can extend their run or settle into a consolidation range.

MarketBeat Merck price history

MarketBeat Merck guidance and consensus

Investing.com Merck performance overview